Here's Why Hangzhou Tigermed Consulting (SZSE:300347) Can Manage Its Debt Responsibly
Dec 14
Have your own idea? Try our Stock Screener
Chinese (SSE) Life Sciences Industry Analysis
UpdatedDec 22, 2024
DataAggregated Company Financials
Companies25
- 7D-1.5%
- 3M35.0%
- 1Y-18.1%
- YTD-16.5%
Over the last 7 days, the Life Sciences industry has dropped 4.2%, driven by a pullback from WuXi AppTec of 1.3%. However, the industry is down 19% over the past year. Looking forward, earnings are forecast to grow by 30% annually.
Industry Valuation and Performance
Has the Chinese Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 22 Dec 2024 | CN¥382.5b | CN¥87.8b | CN¥11.2b | 39.7x | 34.2x | 4.4x |
| Tue, 19 Nov 2024 | CN¥363.9b | CN¥87.8b | CN¥11.2b | 37.6x | 32.5x | 4.1x |
| Thu, 17 Oct 2024 | CN¥346.2b | CN¥88.2b | CN¥12.4b | 31.4x | 28x | 3.9x |
| Sat, 14 Sep 2024 | CN¥279.9b | CN¥88.2b | CN¥12.4b | 27.5x | 22.6x | 3.2x |
| Mon, 12 Aug 2024 | CN¥291.8b | CN¥87.6b | CN¥12.6b | 27.3x | 23.2x | 3.3x |
| Wed, 10 Jul 2024 | CN¥267.4b | CN¥88.3b | CN¥13.4b | 23.1x | 20x | 3x |
| Fri, 07 Jun 2024 | CN¥303.4b | CN¥88.3b | CN¥13.4b | 26.5x | 22.7x | 3.4x |
| Sun, 05 May 2024 | CN¥327.0b | CN¥89.0b | CN¥13.5b | 30.1x | 24.2x | 3.7x |
| Tue, 02 Apr 2024 | CN¥345.6b | CN¥90.3b | CN¥15.0b | 34.9x | 23x | 3.8x |
| Thu, 29 Feb 2024 | CN¥353.5b | CN¥91.2b | CN¥15.8b | 31.1x | 22.4x | 3.9x |
| Sat, 27 Jan 2024 | CN¥404.2b | CN¥91.1b | CN¥16.1b | 33.7x | 25.1x | 4.4x |
| Mon, 25 Dec 2023 | CN¥468.6b | CN¥91.1b | CN¥16.1b | 36.1x | 29.1x | 5.1x |
| Wed, 22 Nov 2023 | CN¥554.0b | CN¥91.1b | CN¥16.1b | 38.8x | 34.5x | 6.1x |
| Fri, 20 Oct 2023 | CN¥522.5b | CN¥92.2b | CN¥18.4b | 34.9x | 28.3x | 5.7x |
| Sun, 17 Sep 2023 | CN¥488.8b | CN¥92.0b | CN¥18.3b | 32.5x | 26.7x | 5.3x |
| Tue, 15 Aug 2023 | CN¥499.5b | CN¥91.6b | CN¥18.6b | 35.2x | 26.9x | 5.5x |
| Thu, 13 Jul 2023 | CN¥447.8b | CN¥91.3b | CN¥18.5b | 34.1x | 24.2x | 4.9x |
| Sat, 10 Jun 2023 | CN¥483.6b | CN¥91.3b | CN¥18.5b | 36.6x | 26.2x | 5.3x |
| Mon, 08 May 2023 | CN¥506.0b | CN¥91.5b | CN¥18.5b | 39.9x | 27.3x | 5.5x |
| Wed, 05 Apr 2023 | CN¥555.4b | CN¥90.1b | CN¥19.2b | 52x | 29x | 6.2x |
| Fri, 03 Mar 2023 | CN¥611.4b | CN¥85.5b | CN¥20.0b | 52.9x | 30.6x | 7.1x |
| Sun, 29 Jan 2023 | CN¥715.1b | CN¥86.6b | CN¥20.8b | 60.6x | 34.4x | 8.3x |
| Tue, 27 Dec 2022 | CN¥572.8b | CN¥86.6b | CN¥20.8b | 47.6x | 27.5x | 6.6x |
| Thu, 24 Nov 2022 | CN¥603.2b | CN¥86.6b | CN¥20.8b | 50.9x | 29x | 7x |
| Sat, 22 Oct 2022 | CN¥559.1b | CN¥78.3b | CN¥18.6b | 47.8x | 30.1x | 7.1x |
| Mon, 19 Sep 2022 | CN¥559.0b | CN¥77.8b | CN¥17.0b | 47.8x | 32.8x | 7.2x |
| Wed, 17 Aug 2022 | CN¥628.5b | CN¥73.4b | CN¥17.1b | 61.4x | 36.7x | 8.6x |
| Fri, 15 Jul 2022 | CN¥729.6b | CN¥69.0b | CN¥15.2b | 71.6x | 48x | 10.6x |
| Sun, 12 Jun 2022 | CN¥649.6b | CN¥69.0b | CN¥15.2b | 63.8x | 42.8x | 9.4x |
| Tue, 10 May 2022 | CN¥571.6b | CN¥68.5b | CN¥15.1b | 57.4x | 37.8x | 8.3x |
| Thu, 07 Apr 2022 | CN¥659.1b | CN¥62.7b | CN¥15.0b | 64.2x | 43.9x | 10.5x |
| Sat, 05 Mar 2022 | CN¥624.5b | CN¥60.9b | CN¥14.0b | 68.4x | 44.5x | 10.3x |
| Mon, 31 Jan 2022 | CN¥625.4b | CN¥57.5b | CN¥12.3b | 67.6x | 50.8x | 10.9x |
| Wed, 29 Dec 2021 | CN¥736.4b | CN¥57.2b | CN¥12.2b | 84.9x | 60.2x | 12.9x |
Price to Earnings Ratio
60.2x
Current Industry PE
- Investors are relatively neutral on the Chinese Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 31.5x.
- The 3-year average PS ratio of 6.3x is higher than the industry's current PS ratio of 4.3x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have declined 2.9% per year over the last three years.
- Meanwhile revenues for these companies have grown 15% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | -1.18% | |
| Healthcare | -2.08% | |
| Life Sciences | -1.52% | |
| Clinical Research and Equipment | -1.52% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 688114 MGI Tech | CN¥52.98 | 3.4% +CN¥707.1m | -37.8% | PS8.5x | |
| 688068 Beijing Hotgen Biotech | CN¥58.56 | 4.9% +CN¥244.6m | 43.4% | PS10.1x | |
| 301230 PharmaResources (Shanghai) | CN¥28.07 | 4.0% +CN¥149.9m | 4.3% | PE557.2x | |
| 688222 HitGen | CN¥13.96 | 0.7% +CN¥39.9m | -5.9% | PE106.1x |
